Last reviewed · How we verify
Intravenous tirofiban before endovascular thrombectomy
Tirofiban is a platelet glycoprotein IIb/IIIa inhibitor that prevents platelet aggregation and thrombus formation during endovascular thrombectomy for acute ischemic stroke.
Tirofiban is a platelet glycoprotein IIb/IIIa inhibitor that prevents platelet aggregation and thrombus formation during endovascular thrombectomy for acute ischemic stroke. Used for Acute ischemic stroke undergoing endovascular thrombectomy.
At a glance
| Generic name | Intravenous tirofiban before endovascular thrombectomy |
|---|---|
| Sponsor | General Hospital of Shenyang Military Region |
| Drug class | Glycoprotein IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Neurology |
| Phase | Phase 3 |
Mechanism of action
Tirofiban reversibly binds to the glycoprotein IIb/IIIa receptor on platelet surfaces, blocking the final common pathway of platelet aggregation by preventing fibrinogen cross-linking. When administered intravenously before endovascular thrombectomy, it reduces thrombotic complications and improves reperfusion outcomes in acute ischemic stroke patients by maintaining vessel patency and preventing thrombus reformation during mechanical clot retrieval.
Approved indications
- Acute ischemic stroke undergoing endovascular thrombectomy
Common side effects
- Bleeding complications
- Thrombocytopenia
- Intracranial hemorrhage
Key clinical trials
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke (PHASE2, PHASE3)
- Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban (PHASE3)
- Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: